LEESHA ELLIS-COX: Open Payments
NPI 1598764698 · BIRMINGHAM, AL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$137,623 in 350 payments from 16 companies in 2025. Trend: 2023 $153,453 · 2024 $170,443 · 2025 $137,623
Speaker / faculty: $107,396Consulting: $11,940Travel & lodging: $10,534Food & beverage: $7,753
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 83 | $65,864 |
| Alkermes, Inc. | 71 | $54,219 |
| E.R. Squibb & Sons, L.L.C. | 38 | $14,214 |
| Vanda Pharmaceuticals Inc. | 30 | $863 |
| Neurocrine BioSciences, Inc. | 26 | $570 |
| Lundbeck LLC | 17 | $369 |
| Teva Pharmaceuticals USA, Inc. | 20 | $350 |
| Otsuka America Pharmaceutical, Inc. | 19 | $274 |
| Janssen Pharmaceuticals, Inc | 10 | $251 |
| Axsome Therapeutics, Inc. | 8 | $191 |
Products named: CAPLYTA, LYBALVI, ARISTADA, COBENFY, FANAPT, INGREZZA, REXULTI, UZEDY.
Industry payments across AL — which companies pay providers there.
